Drug Trial Radar · NCT06211751
A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy
Last checked: Nov 19, 2026Latest source record: Jan 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
208
Planned (sponsor's estimate)
Start
Jan 2024
Primary completion
Dec 2025
Study completion Jun 2026
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open, multi-cohort clinical study. The first phase is a dose escalation study and the second phase is a dose expansion study based on the Maximum tolerated dose (MTD) / Recommended Phase II Dose (RP2D) obtained in the first phase. The purpose is to evaluate the safety and preliminary efficacy of TQB3909 tablets combined with TQB3702 tablets in hematologic malignancy subjects.
Conditions
- Hematologic Malignancy
Interventions
TQB3909 tabletsDrug
TQB3909 is a protein inhibitor.
TQB3702 tabletsDrug
TQB3702 is a kinase inhibitor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limited toxicity (DLT)Time frame: Baseline up to 104 weeks
- Adverse events (AE)Time frame: Baseline up to 104 weeks
- Serious adverse events (SAE)Time frame: Baseline up to 104 weeks
- Clinical laboratory abnormalitiesTime frame: Baseline up to 104 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Henan Cancer Hospital
Zhengzhou, Henan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.